secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001645113-26-000043
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure Q1 net revenue $174M (+12% YoY); raises FY2026 guidance; Optune Pax launch
--------------------------------------------------------------------------------

- Net loss of $71.1M ($0.62 per share); Adjusted EBITDA of -$0.3M.
- Gross margin improved to 78% (from 75%) on lower array costs.
- Optune Pax FDA approved for locally advanced pancreatic cancer; 169 prescriptions, 83 active patients as of March 31, 2026.
- FY2026 revenue guidance raised to $690M-$710M (from $675M-$705M); Adj. EBITDA guidance narrowed to -$15M-$0M.
- PANOVA-4 Phase 2 met primary endpoint with 74% disease control rate vs 48% historical control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000043/0001645113-26-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000043/nvcr-20260430.htm
  HTML page:      https://secwatch.observer/filing/0001645113-26-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer